{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-002162","form_type":"8-K","ticker":"BEAM","cik":"0001745999","company_name":"Beam Therapeutics Inc.","filed_at":"2022-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.054823+00:00","generated_at":"2026-06-27T03:45:41.406652+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Beam reports $1.2B cash post-Pfizer deal; H2 2022 IND milestones set for SCD programs","bullets":["Pfizer collaboration: $300M upfront, up to $1.35B milestones for in vivo base editing programs.","Cash $1.2B including Pfizer payment; Q4 net loss $64.7M ($0.95/shr), FY net loss $370.6M ($5.77/shr).","Planned H2 2022 IND submissions: BEAM-101 (SCD Phase 1/2), BEAM-102 (SCD), BEAM-201 (T-ALL/TLL).","IND-enabling studies for BEAM-301 (liver-targeted GSDIa) in 2022; second CAR-T candidate nomination due.","R&D expenses $96.8M Q4 (up from $32.5M), G&A $17.8M Q4 (up from $8.4M) YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-002162","json":"https://secwatch.observer/filing/0000950170-22-002162.json","markdown":"https://secwatch.observer/filing/0000950170-22-002162.md","text":"https://secwatch.observer/filing/0000950170-22-002162.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1745999/000095017022002162/0000950170-22-002162-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1745999/000095017022002162/beam-20220228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T03:45:41.406652+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}